MAPT and Alzheimer disease: IONIS-MAPTRx, a PS 2MOE ASO targeting MAPT in CNS, administered IT at 4-week intervals, is currently in a phase one clinical study in mild AD patients conducted by Ionis/Biogen (Table 2; IONIS-MAPTRx, 2020).